David Miklos, MD, Stanford University

DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.

Use of CAR T-Cell Therapies in Earlier Lines of DLBCL

Kami J. Maddocks, MD;Jason Westin, MD;David Miklos, MD, Stanford University;Richard T. Maziarz, MD;Grzegorz S. Nowakowski, MD

February 24th 2022

Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.

Monoclonal Antibodies for Treatment of R/R DLBCL

Kami J. Maddocks, MD;Jason Westin, MD;David Miklos, MD, Stanford University;Richard T. Maziarz, MD;Grzegorz S. Nowakowski, MD

February 17th 2022

Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.

Real-World Data With CAR-T Therapies in R/R DLBCL

Kami J. Maddocks, MD;Jason Westin, MD;David Miklos, MD, Stanford University;Richard T. Maziarz, MD;Grzegorz S. Nowakowski, MD

February 17th 2022

Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.

Safety With CAR-T Therapies in R/R DLBCL

Kami J. Maddocks, MD;Jason Westin, MD;David Miklos, MD, Stanford University;Richard T. Maziarz, MD;Grzegorz S. Nowakowski, MD

February 10th 2022

Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.

CAR-T Therapies in R/R DLBCL

Kami J. Maddocks, MD;Jason Westin, MD;David Miklos, MD, Stanford University;Richard T. Maziarz, MD;Grzegorz S. Nowakowski, MD

February 10th 2022

Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.

CAR-T Therapy

Kami J. Maddocks, MD;Jason Westin, MD;David Miklos, MD, Stanford University;Richard T. Maziarz, MD;Grzegorz S. Nowakowski, MD

February 3rd 2022

Dr Miklos provides an overview of chimeric antigen receptor T (CAR-T) cell therapy.

Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma

Kami J. Maddocks, MD;Jason Westin, MD;Richard T. Maziarz, MD;Grzegorz S. Nowakowski, MD;David Miklos, MD, Stanford University

February 3rd 2022

Dr Nowakowski discusses patient heterogeneity and treatment of relapsed vs refractory patients with DLBCL.

Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Kami J. Maddocks, MD;Jason Westin, MD;David Miklos, MD, Stanford University;Richard T. Maziarz, MD;Grzegorz S. Nowakowski, MD

January 24th 2022

A panel of diffuse large B-cell lymphoma experts discuss patient criteria and treatment selection in relapsed/refractory DLBCL.

Front-Line Treatment of DLBCL

Kami J. Maddocks, MD;Jason Westin, MD;David Miklos, MD, Stanford University;Richard T. Maziarz, MD;Grzegorz S. Nowakowski, MD

January 24th 2022

Drs Westin, Miklos, and other panelists discuss the standard of care and emerging frontline treatments for diffuse large B-cell lymphoma.

Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease

Kami J. Maddocks, MD;Jason Westin, MD;David Miklos, MD, Stanford University;Richard T. Maziarz, MD;Grzegorz S. Nowakowski, MD

December 23rd 2021

A panel of oncologists talks about diffuse large B-cell lymphoma, what patient and disease factors one should take into account when thinking about DLBCL.

Ongoing Issues in CAR T-Cell Therapy and Lymphoma

Stephen J. Schuster, MD, Abramson Cancer Center;Caron A. Jacobson, MD, Dana-Farber Cancer Institute;Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center;David Miklos, MD, Stanford University;Loretta J. Nastoupil, MD, MD Anderson Cancer Center

David Miklos, MD, Stanford University

Articles

Latest Updated Articles

Latest Conference Coverage